Figure 25 is titled “Evidence network: comparisons, and number of subjects for each, included in network meta-analysis.” The figure is a network diagram showing the number of subjects in the included 33 trials and 13 active treatments (4,491 subjects) that included CAPS-measured PTSD symptoms. The figure is described further in the section entitled “Network Meta-Analysis of Pharmacotherapy Trials” as follows: “A network diagram illustrates the number of subjects contributing to each comparison; thickness of lines connecting each drug-drug or drug-placebo is directly proportional to the number of trials with available data for that comparison.” The diagram has “placebo” in the center of the diagram with several lines or arms (12) extended from the center. In a clockwise direction, the first line represents trials comparing venlafaxine and placebo, 687 subjects included. The second line represents trials comparing fluoxetine and placebo, 835 subjects included. The third line represents trials comparing risperidone and placebo, 419 subjects included. The fourth line represents trials comparing topiramate and placebo, 142 subjects included. The fifth line represents trials comparing olanzapine and placebo, 47 subjects included. The sixth line represents trials comparing tiagabine and placebo, 232 subjects included. The seventh line represents trials comparing divalproex and placebo, 85 subjects included. The eighth line represents trials comparing paroxetine and placebo, 886 subjects included; an additional line to the left of this line represents a trial comparing paroxetine to desipramine, 88 subjects included. The ninth line represents trials comparing buproprion and placebo, 28 subjects included. The tenth line represents trials comparing prazosin and placebo, 111 subjects included. The eleventh line represents trials comparing citalopram and placebo, 35 subjects included; an additional line to the left of this line connects with sertraline and represents trials comparing citalopram and sertraline, 48 subjects included. The twelfth and final line represents trials comparing sertraline and placebo, 1085 subjects included; an additional line to the left of this line connects with venlafaxine and represents trials comparing sertraline and venlafaxine, 352 subjects included.

Figure 25Evidence network: comparisons, and number of subjects for each, included in network meta-analysisa

aSample sizes may not add up to those in the diagram because of multiarm studies.

CAPS = Clinician-Administered PTSD Scale; N = number; PTSD = posttraumatic stress disorder.

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 207.
Forman-Hoffman V, Middleton JC, Feltner C, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.